과민성대장증후군 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Irritable Bowel Syndrome Treatment Market size is expected to reach USD 10.28 Billion in 2034 from USD 4.60 Billion (2025) growing at a CAGR of 9.34% during 2026-2034.

The global irritable bowel syndrome treatment market is growing steadily due to the increasing prevalence of digestive disorders worldwide. Irritable bowel syndrome (IBS) is a common gastrointestinal condition that causes symptoms such as abdominal pain, bloating, diarrhea, and constipation. Rising awareness about digestive health and improved diagnostic methods are encouraging more patients to seek treatment for this condition.

One of the major drivers of the market is the growing demand for effective medications and therapies that help manage IBS symptoms. Pharmaceutical companies are developing new drugs and treatment options aimed at improving patient outcomes and quality of life. In addition, lifestyle changes, dietary management, and probiotic therapies are becoming increasingly popular in managing the condition.

In the future, the IBS treatment market is expected to grow as research continues to improve understanding of the disease and its underlying causes. Advances in personalized medicine and targeted therapies may lead to more effective treatment options for patients. As healthcare systems focus more on gastrointestinal health and patient care, the demand for IBS treatments will continue to increase.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• IBS-C
• IBS-D

By Drug Class

• Xifaxan
• Linzess/Constella
• Viberzi
• Amitiza
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

COMPANIES PROFILED

• Ironwood Pharmaceuticals Inc, Allergan, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, AstraZeneca, Sanofi SA, Sebela Pharmaceuticals Inc, Bausch Health, Synthetic Biologics Inc, Ardelyx
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. IBS-C Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. IBS-D Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Xifaxan Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Linzess/Constella Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Viberzi Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Amitiza Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Drug Class
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Drug Class
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Drug Class
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Drug Class
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Drug Class
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Ironwood Pharmaceuticals Inc
  • 9.2.2 Allergan
  • 9.2.3 Astellas Pharma Inc
  • 9.2.4 Takeda Pharmaceutical Company Limited
  • 9.2.5 AstraZeneca
  • 9.2.6 Sanofi S.A
  • 9.2.7 Sebela Pharmaceuticals Inc
  • 9.2.8 Bausch Health
  • 9.2.9 Synthetic Biologics Inc
  • 9.2.10 Ardelyx